Faizan Farooque

Faizan Farooque

InvestorPlace Contributor

Expertise: Real estate investment trusts (REITs), SPACs, Cryptocurrencies

Education: BSc (Hons) Degree in Applied Accounting, Oxford Brookes University; Introduction to Data Analysis Using Excel, Rice University; Excel Skills for Business: Intermediate, Macquarie University

About Faizan
Faizan Farooque is a finance journalist who has reported on the latest trends in the stock market for many years. He helps people by providing advice about saving and investing and keeping up with what’s happening in the financial world.

Faizan is writing for InvestorPlace.com, GuruFocus, and TipRanks and has previously worked as a financial journalist and data analyst for S&P Global. He can analyze company filings from sources like SEC, FINRA, and others to help identify potential investment opportunities. Researching specific industries is also something he does to provide industry insight for clients.

Faizan deeply understands the market and how to read the financial tea leaves to anticipate where things are headed. His expertise gives readers an insider’s perspective on what’s happening in the finance world so they can make smart decisions.

Recent Articles

7 Stocks to Buy to Hone in on Ray Dalio’s Reliable Favorites

By Faizan Farooque, InvestorPlace Contributor

Most analysts agree we could see a sharp price correction soon. Before that happens, take a look at these Ray Dalio-preferred stocks to buy.

Algorand Will Grow as Its List of Partners and Developers Increases

By Faizan Farooque, InvestorPlace Contributor

Algorand's developers believe their blockchain can validate transactions quickly, while avoiding technical issues that affect other designs.

Ripple Promises Growth for Investors — But at Their Own Risk

By Faizan Farooque, InvestorPlace Contributor

With Ripple, anyone can send money around without hassle in a secure manner, making it one of the most sought-after digital tokens around.

A Move Into Novavax Stock Makes Sense Ahead of Several Near-term Catalysts

By Faizan Farooque, InvestorPlace Contributor

NVAX is a disappointing stock because of manufacturing issues and filing delays hampering progress, but there are brighter days ahead for the vaccine maker.

5 Stocks That Could Get Pricked by Corporate Vaccine Mandates

By Faizan Farooque, InvestorPlace Contributor

Corporate vaccine mandates may negatively impact these five companies looking to put the pandemic behind them.

Load More